3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Triple Negative Breast Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Breast Neoplasms
1
Interventions
Rituximab
43
Cyclophosphamide
26
fludarabine
15
ibrutinib
14
Vincristine
11
Prednisone
11
Doxorubicin
11
pirtobrutinib
10
Bendamustine Hydrochloride
10
obinutuzumab
9
polatuzumab vedotin
6
Inotuzumab Ozogamicin
6
tocilizumab
5
pembrolizumab
5
glofitamab
5
Gemcitabine
5
zanubrutinib
4
venetoclax
4
ublituximab
4
Lenalidomide
4
Brentuximab Vedotin
4
Antigens, CD19
4
tazemetostat
3
acalabrutinib
3
Everolimus
3
DTRMWXHS-12
3
veltuzumab
2
sepantronium
2
iberdomide
2
denileukin diftitox
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, B-Cell
×
tenalisib
×
Clear all
NCT02017613
2016-06-24
PI3K
Rhizen Pharmaceuticals SA
Phase 1
Completed
35 enrolled